Cell & Bioscience launches with BioMed Central

Cell & Bioscience, a new open access journal, has launched today with BioMed Central as the official journal of the Society of Chinese Bioscientists in America (SCBA).

Led by Editor-in-Chief, Yun-Bo Shi, Cell & Bioscience publishes high-impact research of broad interest in all areas of the life sciences, covering fields such as molecular and cell biology, cancer biology and immunology. In his inaugural editorial, Yun-Bo Shi comments on the rapid growth of open access publishing and the need for a new journal in the field to reach both Western and Asian audiences.

The SCBA, founded 26 years ago, is the largest organization of Chinese bioscientists outside of Asia. "As we enter the 21st century, science in Asia is poised for further accelerated growth, and a professional society like the SCBA is arguably very well-positioned to promote the interests of the Western and the Asian scientific communities", says Kuan-Teh Jeang, President of SCBA in his editorial introducing readers to the SCBA.

The first articles published today include research from T-C Wu and colleagues describing the influence of an oncogenic microRNA on T cell-mediated immune responses, and from Xin Wang and colleagues on the activation of microRNA expression in hepatocellular carcinoma.

Biennially, the society organizes an international meeting attended by up to 2,000 bioscientists. The next meeting (The 13th SCBA International Symposium), entitled ‘Bioscience for the 21st century: Emerging Frontiers and Evolving Concepts’, is taking place in Guangzhou, China, on the 25th — 29th of July 2011. The SCBA is currently inviting submissions of abstracts from a variety of topics within the breadth of the biosciences. The deadline for submissions is the 10th of April 2011.

For further information about Cell & Bioscience, please visit the journal’s homepage or, for guidelines on how to submit your own work, please see the instructions for authors.

View the latest posts on the On Biology homepage

Comments

By commenting, you’re agreeing to follow our community guidelines.

Your email address will not be published. Required fields are marked *